Senicapoc

Research use only, not for human use.

A potent, selective Gardos channel blocker that blocks Ca(2+)-induced rubidium flux from human RBCs (IC50=11 nM) and inhibits RBC dehydration (IC50=10-50 nM).

A potent, selective Gardos channel blocker that blocks Ca(2+)-induced rubidium flux from human RBCs (IC50=11 nM) and inhibits RBC dehydration (IC50=10-50 nM); shows greater potency and selectivity than Clotrimazole; increases RBC K(+) content and hematocrit (Hct), decreases corpuscular hemoglobin concentration (MCHC) in a transgenic mouse model of sickle cell disease (SAD); orally active.Other Indication Phase 3 Discontinued.

——

——

ICA-17043

Cell Cycle/DNA Damage

Potassium Channel

Gardoschannel

Other Indications

Other Disease

289656-45-7

323.336

C20H15F2NO

>98% (HPLC)

10 mM in DMSO

C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N

Benzeneacetamide, 4-fluoro-.alpha.-(4-fluorophenyl)-.alpha.-phenyl-

(-20℃)

With Ice Pack

≥ 2 years